WO2011019668A1 - Formulation cosméceutique topique et procédés de préparation et d’utilisation afférents - Google Patents

Formulation cosméceutique topique et procédés de préparation et d’utilisation afférents Download PDF

Info

Publication number
WO2011019668A1
WO2011019668A1 PCT/US2010/044919 US2010044919W WO2011019668A1 WO 2011019668 A1 WO2011019668 A1 WO 2011019668A1 US 2010044919 W US2010044919 W US 2010044919W WO 2011019668 A1 WO2011019668 A1 WO 2011019668A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
liposomes
liposome
formulations
Prior art date
Application number
PCT/US2010/044919
Other languages
English (en)
Inventor
Melissa Mao
John A. Garruto
Daniel Young
Original Assignee
Meltology, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meltology, Llc filed Critical Meltology, Llc
Publication of WO2011019668A1 publication Critical patent/WO2011019668A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24—Thermal properties
    • A61K2800/242—Exothermic; Self-heating; Heating sensation

Definitions

  • This invention relates to topical cosmeceuticals, and formulations thereof. In one embodiment, it relates to heat-enhanced transdermal delivery of cosmeceuticals using liposome-encapsulated delivery vehicles.
  • Cosmeceuticals are formulated to enhance the efficacy of cosmetics.
  • cosmeceutical formulations are administered topically to minimize or reverse the effects of aging on the appearance of skin.
  • Complex cosmeceutical formulations are often formulated into a delivery system, such as particles, emulsions, liposomes, or the like.
  • Liposomes can be used as delivery systems for pharmaceuticals and other topically administered materials. When liposomes are applied to the skin, they are able to flow into and through the stratum comeum, and may also be able to merge with cellular membranes and release their active materials within the cell. Thus, the liposomal delivery system is quite effective and efficient as most aqueous-based materials are not able to penetrate the skin's permeability barrier and reach the dermal layer.
  • a cosmeceutical composition for topical administration comprising: a yeast cell lysate; a fatty acid-peptide conjugate; a plant stem cell extract; an enzyme or coenzyme having antioxidant activity; and a microalgae cell extract.
  • Another aspect includes the above formulation incorporated into a liposomal delivery system, and/or when the beneficial effects of the composition is enhanced when heated above room temperature (e.g. above 24 0 C).
  • a method for enhancing the delivery of the above composition to skin comprising: topically applying the composition topically to the skin; and applying a controlled heat to the skin during or after administration.
  • the step of applying controlled heat may be achieved with an exothermically heated material.
  • the exothermically heated material may be in the form of a mitt, bootie, bonnet, mask or body strip.
  • an apparatus for heat- enhanced topical delivery of the above composition comprising: an amount of the composition of claim 1 applied to a skin-side of a self-heating fabricated material, wherein the fabricated material further comprises an exothermic material, wherein the exothermic material is activatable by an aqueous solution.
  • the aqueous solution may be saline.
  • This cosmeceutical formulation comprising at least five ingredients that are optimized for their synergistic effect on the appearance of skin.
  • This cosmeceut ⁇ cal formulation includes, as the active ingredients: yeast cell lysates, fatty acid-peptide conjugate, plant stem cell extract, bacterial antioxidant enzyme extract and niicroalgae cell extract.
  • yeast cell lysates which include live yeast cell derivatives ("LYCD"), are effective in the field of skin treatment and can be applied in the form of lotions, creams and oils.
  • LYCD live yeast cell derivatives
  • a wide variety of yeast cell lysates are contemplated to be effective in the various formulations of the present invention.
  • the yeast cell lysate may be a stressed yeast cell lysate which is capable of enhancing oxygen respiration, promoting skin soothing and smoothing effects and simulating collagen synthesis.
  • This stressed yeast cell lysate may contain tissue respiratory factor ("TRF"'), which is a live yeast cell derivative that has been shown to have therapeutic applications in skin cosmetics.
  • TRF tissue respiratory factor
  • Live yeast cell derivatives can be manufactured by fermenting various types of yeast culture, such as Saccharomyces cerevisiae.
  • One method of producing a stressed yeast cell lysate is by subjecting yeast cells to irradiation with ultraviolet light and heat, which causes the yeast cells to produce a variety of protective substances. Once this has occurred, the yeast cell walls are broken down through use of a proteolytic enzyme (i.e., they are lysed), and then centrifuged to leave only cellular protoplasm behind.
  • TRF is composed of the low molecular weight glycosidic : peptide fractions of the lysate, with a ratio of 1 :3. The residual glycopeptide linkages are through the amino acid asparagine residues. Because TRF is prepared from cell lysates of live yeast cells, additional trace quantities of coenzymes, vitamins, amino acids and minerals, which are also included in the lysate, are co-isolated, which enhances the therapeutic capabilities of TRF in these pharmaceutical/cosmetic preparations. TRF's moisturizing effect is accomplished by increasing uptake of moisture by nascent protein and increasing oxygen utilization in the skin.
  • TRF can increase oxygen respiration in cultured human dermal fibroblasts by up to 1 17% in comparison to an untreated control. Further, it has also been demonstrated that TRF can promote procollagen synthesis and significantly increase hyaluronic acid synthesis in human dermal fibroblasts when compared to an untreated control.
  • TRF Tride-TRF
  • Brooks Industries South Plainfield, NJ.
  • Formulations of fatty acid-peptide conjugates in the form of biomimetic oligopeptides used in the various formulations of the present invention may be natural or synthetic oligopeptides having a sequence of 20 amino acids or less, and sometimes 3, 4 and 5 amino acids, which correspond to a fragment of a protein of the extracellular matrix in the dermis, such as al-pro-collagen, a2-collagen 1 , elastin, tropoelastin, fibronectin, laminin-5 or immunoglobulin IgG.
  • Biomimetic oligopeptides upon application, may act as messengers of a fake aggression on skin cells, thereby triggering activation of a mechanism similar to wound healing or matrix renewal. They have been found to be able to exercise feedback control on the process of connective tissue renewal and cell proliferation, for example by stimulating neo-synthesis of collagen I, III, IV, fibronectin, Iaminin-5 and/or
  • glycosaminoglucans by fibroblasts.
  • Non-limiting examples of biomimetic oligopeptides used in the compositions of the present invention may include the tripeptide Palmitoyl-GIycyl-Histidyl-Lysine (PaI- GHK), the tetrapeptide Palmitoyl-Glycyl-Glutaminyl-Prolyl- Arginine (PaI-GQPR) and a mixture of PaI-GHK and PaI-GQPR, also known as MatrixylTM 3000 which is manufactured by Sederma S.A.S. (Le Perray-en Yvelines Cedex, France).
  • PaI- GHK tripeptide Palmitoyl-GIycyl-Histidyl-Lysine
  • PaI-GQPR tetrapeptide Palmitoyl-Glycyl-Glutaminyl-Prolyl- Arginine
  • MatrixylTM 3000 also known as MatrixylTM
  • a number of plant cells have been used in cosmetic formulations for the treatment of various skin conditions.
  • dedifferentiated plant cells or piant "stem cells" have been studied for their therapeutic applications for treating skin.
  • One such plant known as Uttwiler spatlauber, is a variety of a Swiss apple that has been studied for its excellent storability properties.
  • Plant stem cells have a complex matrix of constituents made up of salts, acids, polyphenols, sugars, fats, proteins and other components. In addition to known components, there is also an unknown fraction of components which may have cosmetic applications. Specifically, it has been shown that plant stem cells contain specific epigenetic factors whose function is to maintain the self-renewal capacity of stem cells.
  • Plant cell extracts have been used for many years in skin care formulations. For instance, it is known to solubilize plant cells in suspension cultures and extract the oil and water soluble agents into empty liposomes to improve both the stability of the extracted agents and their transportation into skin.
  • One method of extracting plant stem cells involves triggering a plant's wound healing mechanism in order to induce the formation of callus cells.
  • This wound healing tissue consists of stem cells.
  • the callus cells, including stem cells, can then be harvested and cultivated in a suspension and homogenized together with liposomes to encapsulate and stabilize both oil and water soluble components.
  • PhytoCellTecTM (Mibelle AG Biochemistry, Switzerland) involves an eight step procedure for preparing plant stem cells: 1) selecting/taking away a small piece of the plan; 2) wounding of plant material to induce callus formation; 3) incubation on agar plates; 4) harvesting of developed callus; 5) cultivation until complete dedifferentiation to obtain stem cells; 6) transfer of the stem cells into a suspension (liquid media); 7) disruption of the stem cells wall; and 8) encapsulation of the stem cell content into liposomes.
  • At least one plant stem cell extract is present in the formulations of the present invention.
  • a non-limiting example of a particularly effective plant stem cell is supplied as PhytoCellTecTM from Malm domestica, manufactured by Mibelle AG Biochemistry (Switzerland).
  • PhytoCellTecTM from Malm domestica, manufactured by Mibelle AG Biochemistry (Switzerland).
  • Bacterial Antioxidant Enzyme Extracts are supplied as Bacterial Antioxidant Enzyme Extracts
  • the formulations of the present invention also further comprise a safe and effective amount of one or more enzymes, enzyme inhibitors or enzyme activators (coenzymes).
  • enzymes are lipases, proteases, catalase,
  • superoxidedismutase amylases, glucuronidases, peroxidases, in particular glutathione peroxidase or lactoperoxidase, ceramidases, hyaluronidases. All of these enzymes may be obtained by extraction from bacteria using fermentation processes. In one
  • the enzyme is an anti-oxidant selected from the group of superoxide dismutase, catalase and peroxidase.
  • enzymes and enzyme complexes that exhibit superoxide dismutase-like properties, glutathione peroxidase-like activity and catalase- like activity.
  • the enzyme or coenzyme activity is involved in the protection against oxidation and is enhanced by applying effective amounts of heat.
  • a number of skin treatment formulations may exhibit a change in the rate of activity due to the presence of heat.
  • the heat- activated ingredient becomes active or exhibits an increased level of enzymatic activity when it is heated to a temperature range of between 40° C and 60° C.
  • various enzyme complexes exhibit higher superoxide dismutase-like activity proportional to increases in heat.
  • Alternative enzyme complexes can exhibit higher glutathione peroxi date- like activity or catalase-like activity as well in response to higher temperatures.
  • various enzyme complexes can also exhibit greater stability of enzymatic activity in response to higher temperatures. Further, some enzyme complexes may also exhibit higher levels of enzymatic activity or stability in response to an increase in UVA irradiation as well.
  • a particularly effective heat enhanced ingredient is found in an extract of Thermus thennophilus, which was discovered in a deep-sea hydrothermal vent in Guaymas Basin (Gulf of California at 2000 m depth). The fermentation of Thermus thennophilus for producing proteins is disclosed in WO 02/066668 A2, incorporated herein by reference.
  • the use of extracts from Thermus thermophilus cultures in cosmetic compositions is known to modulate the cutaneous concentration of ceramides, to stimulate the immune system to provide protection as a detoxifying agent and against free radicals, especially oxygen peroxide.
  • Thermus thermophilus extracts have been shown to exhibit anti-oxidant properties such as removal of superoxide anions and peroxidase activity, as well as an increase in resistance to UVA-induced peroxidation.
  • Thermus thermophilus extracts have also been shown to confer upon UVA- irradiated fibroblasts the ability to retain anchor collagen at a high rate and retain high levels of catalase activity.
  • Various other benefits may include reduced membrane lipid peroxidation and reduced UVA- induced oxidative lesions of DNA in fibroblasts.
  • a Thermus thermophilus extract is available commercially from Sederma, (Le Perray-en Yvelines Cedex, France) under the product label VenuceaneTM. e. Microalgae Extracts
  • a safe and effective amount of a microalgae-derived active ingredient is also included in the various fo ⁇ nulations of the present invention.
  • Various microalgae can be found in inhospitable environments such as salt lakes and undergo a variety of stresses such as high osmotic pressure, high UV-levels and high oxygen levels.
  • various microalgae extracts have been shown to confer beneficial effects in cosmeceutical applications.
  • Microalgae are a rich natural source of vitamins, minerals and other components essential for skin care.
  • carotenoids are an abundant component of microalgae extracts.
  • an active ingredient derived from Dunaliella salina is particularly effective in the treatment of skin. Extracts of Dunaliella salina have been shown to stimulate ATP-production of mitochondria and improve cell turnover in skin cells.
  • a commercially optimized form of Dunaliella salina is available from Pentapharm (Basel, Switzerland) under the trade name PEPHA ® -CTIVE.
  • the concentration of ingredients can be prepared as follows:
  • the various formulations may also optionally include a wide range of excipients.
  • excipients commonly used in the cosmetic and personal care industry are described in The CTFA Cosmetic Ingredient Handbook, (9 l Ed., 2002), which is incorporated by reference herein. These ingredients will be used in amounts which are conventional.
  • Certain cosmetic formulations contain ingredients that must be capable of penetrating through various external layers of the skin to interact with cells blow these external layers. This sometimes requires the use of complex delivery systems to make otherwise unpenetrating and unstable compounds more efficacious.
  • ingredients that are highly charged, insoluble and/or have a high molecular weight sometimes have limited usefulness unless they are coupled to a carrier or incorporated into a delivery vehicle.
  • liposomes have been described for use in the cosmetic field.
  • An advantage of using liposome formulations is the ability of these substances to mimic naturally occurring cellular membrane substituents. This encourages absoiption and intracellular uptake, which results in delivery of the liposome contents into the inner skin layers, and cell cytoplasm.
  • Liposomes are tiny spherical lipid vesicles which form when phospholipids hydrate in water. These vesicles' membranes are similar in structure to the outer membranes of biological cells. Phospholipids are natural moisture barrier components of the skin, aiding in cellular repairs and turnover. Under low shear mixing conditions, they tend to be multilamellar structures comprised of oriented bilayers of phospholipids molecules surrounding concentric aqueous compartment. Further processing can produce unilamellar liposomes, which are small in size, uniform, and stable
  • Liposomes are generally produced using soy lecithin, whose main compound is phosphatidylcholine. Lecithin processed through a microfluidizer forms the unilamellar structure mentioned earlier. Because phosphatidylcholine is known as a penetration enhancer, this property is usually associated with liposomes. Liposomes are the vesicles which transport cosmetic agents more easily into the horny layer; moreover, the conditioning effect causes the horny layer to become a depot for these agents. Measurements of systematically active pharmaceuticals/cosmeceuticals reveal that an increase of penetration is not necessarily correlative with an increase of permeation.
  • Liposomes can generally be made available in two fo ⁇ ns, dispersed and emulsified. Dispersed liposomes are produced with solutions of water-soluble agents which are captured in the interior compartments of the vesicle, and are present in the continuous space of the dispersion. Dispersed liposomes are generally 200nm or less in diameter, and are translucent in appearance. Emulsified liposomes capture lipids within the bilayer of the vesicle, which tends to enlarge the size of the vesicle. Emulsified liposomes range in size up to 300nm, and are opaque in appearance.
  • the capture capability of one gram of phospholipids-based liposome with an average diameter of 70nm is 2.75 ml/gm of aqueous solution in a dispersed liposome.
  • the lipid capture capacity in an emulsified liposome is 1.67 ml/gm.
  • Spherical liposomes of this size may contain an excess of 30,000 phospholipid molecules with an aggregate "Molecular Weight" exceeding 24,000,000. Regardless of capture capability, all cosmetic liposmes contain "free" material in the continuous phase.
  • liposomes for skin care cosmetics were primarily composed of phospholipid choline esters of phosphoric acid and a mixture of fatty acid diglycerid.es. Phosphatides are constituents of living cells and affect cell permeability, metabolism, and body function. In liposome forms, cosmetic ingredients exhibit better stability, penetration, and efficacy at lower usage levels.
  • liposomes When liposomes are "filled” with various actives, they can penetrate the stratum corneum and bring hydration and actives through the top layers of the epidermis, with penetration stopping at the "end” of the living epidermal cells.
  • Liposomes are hydrated bilayer structures, which are readily compatible with the peridermal lipids (the skin's primary moisture barrier), which exist as lamellar layers.
  • liposomes When liposomes are applied to the skin, they interact with proteins, carbohydrates and the lipids that compose cell membranes, in a manner similar to that of the cell membranes' own lipid bilayer. It is believed that liposomes partially bind to keratin in the homy layer of the skin.
  • a special quality of liposomes is that they enable water-soluble and water- insoluble materials to be used together in a formulation without the use of surfactants or emulsifiers. Water-soluble materials are dissolved in the water in which the
  • phospholipids are hydrated, and when the liposomes form, these materials are trapped in the aqueous center.
  • the liposome wall being a phospholipid membrane, holds fat- soluble materials, such as oil.
  • Polyunsaturated vegetable phospholipids such as lecithin may enhance skin cell metabolism by making the membranes more fluid.
  • Phospholipids particularly polyunsaturated phospholipids, may have an additional benefit: the liposomes ultimately reach the sebaceous glands, where the linoleic acid in these compounds can supplement the supply of efa (essential fatty acid). These glands require linoleic acid to function, and an insufficient supply can lead to increased pimple and blackhead formation.
  • efa essential fatty acid
  • the releasing of materials captured within the liposome walls when in contact with skin cell membranes may be more than a coincidence.
  • Liposomes have excellent substantivity to keratin (skin and hair) and moisturizers encapsulated in liposomes have been shown to be resistant to washing and removal from the skin.
  • Liposomal preparations may be dosage dependant, requiring a good level of high- quality liposomes within a given formulation, In addition to the dosage dependence for efficacy, the following principles are important in topical liposome formulations: [0053] Surfactants significantly affect the behavior of liposomes. Soaps rapidly (albeit reversibly) break liposomes down into smaller particles; thus, liposomal liquid soaps or shampoos generally cannot easily be formulated. However, liposomes are quite stable in products with amphiphilic surfactants, such as ethanol or ethylene glycol (the vesicles then to be relatively small in alcohol-containing products.)
  • Liposomes which are most useful for the delivery of cosmetic ingredients are often complex formulations containing mixtures of different lipophilic substituents. These complex mixtures allow for optimization of the physical properties of the liposomes, such as pH sensitivity, temperature sensitivity and size.
  • the inventors have recognized that certain temperature sensitive liposome constituents can be used to formulate cosmetic ingredient-containing liposomes that destabilize at increased temperature. This has been shown to promote delivery of the liposome contents after application.
  • sterols in liposomes are also possible.
  • the presence of sterols in liposome formulations results in enhanced stability, both in vitro and in vivo.
  • Liposome formulations for the delivery of biomolecules which contain organic acid derivatives of sterols, such as cholesterol or vitamin D have been reported to be easier to formulate than their non-derivatized water-insoluble equivalents
  • Lipid aggregates can take the form of completely closed structures made up of a lipid bilayer containing an encapsulated aqueous volume (i.e. unilamellar liposomes), or they may contain more than one concentric lipid bilayer separated by an aqueous volume (i.e. multilamellar liposomes).
  • Each lipid bilayer is composed of two lipid monolayers, each of which has a hydrophobic (nonpolar) "tail” region and a hydrophilic (polar) "head” region. In the bilayer, the hydrophobic "tails” of the lipid monolayers orient toward the inside of the bilayer, while the hydrophilic "heads” orient toward the outside of the bilayer.
  • Liposomes may be made by a variety of techniques known in the art. (See, for example, Bangham et al ., J. MoI. Biol., 13: 238-252(1965), incorporated by reference in its entirety herein). These methods generally involve first dissolving and mixing the lipids in an organic solvent, followed by evaporation. Then an appropriate amount of the aqueous phase is mixed with the lipid phase, and then allowed to incubate for a sufficient time for the liposome to form.
  • the aqueous phase will generally consist of the biomolecules in suspension with other solutes, such as buffers or sugars.
  • the liposomes of the present invention are comprised of the lipids, such as an anionic lipid (for example,
  • the present liposomal formulations may further include a lysolipid, such as
  • lysophosphatidylcholine lysophosphatidylethanol amine, or a lyso form of a cationic lipid species.
  • the liposome can also include optional substituents, such as sterols, glycolipids, tissue or organ targeting substances such as antibodies or proteins, fatty acids, or any other natural or synthetic lipophilic or amph philic compounds.
  • substituents such as sterols, glycolipids, tissue or organ targeting substances such as antibodies or proteins, fatty acids, or any other natural or synthetic lipophilic or amph philic compounds.
  • Suitable sterols for inclusion into the liposome include, but are not limited to, cholesterol and Vitamin D, and are included in the liposome formulations as stabilizers.
  • the liposomes of the present invention can be designed to be sensitive to alterations in the temperature of the surrounding environment.
  • the temperature- sensitivity of such liposomes allows the release of compounds entrapped within the interior aqueous space of the liposome, and/or the release of compounds associated with the lipid bilayer, at a target site that is either heated or that is at an intrinsically higher temperature than the site of application, which would be expected for application to the skin, since the inner skin layers are at a higher temperature than the external skin surface.
  • Liposome bilayers of the present invention may include (in addition to a primary or main lipid component) lysolipid, or another surface active agent(s).
  • lysolipid or another surface active agent in the liposome b ⁇ ayer enhances the release of compounds when the liposome temperature reaches the gel-to-liquid crystalline phase transition temperature of the primary lipid component.
  • the presence of the lysolipid (or other surface active agent) also causes the liposome to release its contents at a slightly lower temperature than that achieved with liposomes composed solely of phospholipids.
  • Liposomes of the present invention are particularly useful in skin delivery, where the liposome contains a compound to be delivered to the inner skin layers. The skin is either artificially heated above body temperature so that it is at or above the gel-to-liquid crystalline phase transition temperature, or the liposome is formulated such that the gel- to-liquid crystalline phase transition temperature of the liposome is at or near body temperature,
  • U.S. Patent No. 5,094,854 (Ogawa et al.), incoiporated by reference in its entirety herein, discloses liposomes in which the osmotic pressure of the cosmetic component- containing solution entrapped in liposomes is 1.2-2.5 times higher than body temperature.
  • the temperature range in which the liposome membrane becomes permeable to material release is stated to be in the range of 40-45 degrees centigrade.
  • Liposomes can comprise a lipid possessing a gel-to-iiquid crystalline transition temperature in the hyperthermic range (e.g., the range of from approximately 38-45 degrees centigrade).
  • phospholipids with a phase-transition temperature of from about 38-45 degrees centigrade are utilized.
  • Such phospholipids include those whose acyl groups are saturated.
  • a particularly preferred phospholipid is dipalmitoylphosphatidylcholine (DPPC).
  • DPPC dipalmitoylphosphatidylcholine
  • DPPC is a common saturated chain (C 16) phospholipid with a bilayer transition of 41.5 degrees centigrade.
  • DPPC 1,2-Dipalmitoyl-sn- Glycero-3-[Phospho-rac-(l -glycerol)]
  • DSPC 1,2- Distearoyl-sn-GlyceiO-3-Phosphocholine
  • the "primary lipid" in a liposome bilayer can be the main lipid component of liposome bilayer material.
  • the phospholipid in a liposome bilayer composed of 70 mole % phospholipid and 30 mole % lysolipid, the phospholipid can be the primary lipid.
  • Liposomes suitable for the present invention can incorporate a relatively-water soluble surface active agent, such as a lysolipid, into a bilayer composed primarily of a relatively water-insoluble molecule, such as a di-chain phospholipid (e.g., DPPC).
  • a relatively-water soluble surface active agent such as a lysolipid
  • a bilayer composed primarily of a relatively water-insoluble molecule, such as a di-chain phospholipid (e.g., DPPC).
  • Effective surface active agents are lysolipids, and a particularly effective surface active agent is monopalmitoylphosphatidylcholine (MPPC), Suitable surface-active agents are those that are compatible with the primary lipid of the bilayer, and that desorb when the lipid melts to the liquid phase. Additional suitable surface-active agents for use in
  • phospholipid bilayers include palmitoyl alcohols, stearoyl alcohols, palmitoyl, stearoyl, polyethylene glycol, glyceryl monopalmitate, glyceryl monooleate, ceramides, PEG- ceramides, and therapeutic lipids.
  • Therapeutic lipids include, for example, C- 18 ether linked lysophoshpatidylchohline.
  • the liposomes incoiporate a bilayer-compatible lysolipid in a phospholipid bilayer, the lysolipid present in the bilayer at a concentration sufficient to enhance the release of contents (e.g., active agent or therapeutic agent) from the liposome, compared to the release of contents that would be achieved using a liposome composed of only lipid alone (i.e., without lysolipid).
  • contents e.g., active agent or therapeutic agent
  • the contents may be contained within the interior of the liposome or in the liposome membrane.
  • enhanced release it is meant that either (a) that a greater percentage of contents is released at a given temperature, compared to the amount of contents released at that temperature by a lipsome with a bilayer composed of phospholipid only; or (b) the contents entrapped in the interior of the liposome are released at a lower temperature than the temperature at which release of contents would occur using a lipsome with a bilayer composed of phospholipid only.
  • Manufacturing liposomes may involve preparation of gel phase liposomes containing a phospholipid, an appropriate surface active agent (such as lysolipid), and the cosmetic ingredients to be encapsulated.
  • the composition contains a percentage of lysolipid such that the surface active agent does not destabilize the membrane at processing temperatures where the bilayer is in the liquid phase, nor at the surface temperature of the skin where the bilayer is in the gel phase. Optimization of percentage of liposome constituents can easily be accomplished by routine optimization.
  • the bilayer becomes unstable and permeable at temperatures at or just above normal human body temperature, resulting in release of entrapped material from the liposome interior.
  • Liposomes may be prepared by any of a variety of techniques that are known in the art. See, e.g., U.S. Pat. No. 4,235,871; Published PCT applications WO 96/14057; New RRC, Liposomes: A practical approach, IRL Press, Oxford (1990), pages 33-104; Lasic D D, Liposomes from physics to applications, Elsevier Science Publishers, Amsterdam, 1993; Liposomes, Marcel Dekker, Inc., New York (1983). Each of the above documents are incorporated by reference herein.
  • the method of preparing liposomes involves mixing the bilayer components in the appropriate proportions in an organic solvent, which is thereafter evaporated to form a dried lipid film.
  • the film is rehydrated (at temperatures above the phase transition temperature of the lipid mixture) using an aqueous solution containing an equilibrating amount of the surface active agent and the desired ingredients to be encapsulated.
  • the liposomes formed after rehydration can be extruded to form liposomes of a desired size.
  • Topical delivery systems are broadly categorized as either transdermal or dermal.
  • Transdermal delivery is the controlled release of cosmetic formulation components through intact skin to obtain beneficial levels systematically and to affect specified targets for specific potposes such as anti-aging, among others.
  • Dermal ingredient delivery is similar to TDD except that the specified target is the skin itself. Cosmetic ingredients, including those for antiaging, known as cosmeceuticals, presumably may have the same site of action.
  • the cosmetic and/or transdermal route is indeed desirable by the industry but the success of DDD and cosmetic active ingredient delivery (CAID) technologies remains limited and faces many challenges, one of which is low skin permeability that hinders the development of DDD/CA1D for
  • the formulations of the present invention may be delivered in vehicles other than liposomes, either dermally or transdermal Iy.
  • delivery vehicles are well characterized in the cosmetic arts. For example, see Rosen, Meyer R. Delivery System Handbook for Personal Care and Cosmetic Products - Technology, Applications and Formulations, William Andrew Publishing, the contents of which are incorporated by reference herein.
  • common skin penetration enhancement techniques include electrically assisted techniquies (ionotophoresis, electroporation, sonophoresis and photophoresis); Stratum comeum bypass (microneedles, stratum corneum ablation by, for example, chemical peels, microdermabrasion, microscission, laser, etc); non-liposome vesicles and particles (nanoparticles, high velocity particles such as powder injection, etc); and stratum comeum modification (hydration, chemical penetration enhancers.)
  • the cosmeceutical formulations of the present invention are administered to the skin's surface in conjunction with the administration of heat.
  • heat is known to enhance the efficacy of transdermal delivery and activity of various topically administrated cosmeceutical ingredients by increasing skin permeability and rate-limiting membrane permeability, as well as by directly enhancing enzyme activity. Diffusion through the skin is a temperature-dependent process, so raising the skin temperature will add thermodynamic drive. Heat is known to increase the activity of many of the active ingredients of the topical formulation. In addition, it confers biophysical affects on the proteins, lipids, and carbohydrates in the cell membranes to which the topical formulation is placed.
  • Heating prior to or during topical application of a substance will dilate penetration pathways in the skin, increase kinetic energy and the movement of compounds in the treated area, thus facilitating absorption. Heating the skin after the topical application of a material will increase that material's absoiption. By increasing skin permeability and rate-limiting membrane permeability, increases in localized temperature can be seen which greatly enhance permeation through the skin. a. Chemically Induced Heating
  • One suitable mechanism for generating heat is through the use of an exothermic composition that generates heat upon activation by a secondary, readily available activator substance.
  • exothermic compositions that can be used may come from the combination of water with strong acids, combining alkalis and acids, polymerization, thermite reactions, aluminum-based reactions, magnesium-iron-based reactions, anhydride reactions, and so forth.
  • One particularly suitable, non-toxic exothermic composition is Lava Gel 1 M (manufactured by Forever Young International, Inc., Escondido, California, USA) which is known to exhibit a very controlled, regulated temperature for an extended period of time, with simply the addition of water or an electrolyte solution, such as saline water (as the secondary compound).
  • other exothermic compositions may be used, accordingly to design preference, including compositions that require activation or moderation by more than one secondary compound or element.
  • the mechanisms for application as described herein can be considered as self-contained units, portable, and also, in some instances, disposable with minimal to no environmental consequence. With a regulated, controlled exothermic reaction, overheating can be avoided, as well as burns that occur from such overheating.
  • the disposable embodiments can be of limited or of single use, whereby complications arising from reuse can be obviated.
  • a limited use or single use unit minimizes the occurrence of cross- contamination, as commonly seen in conventional application systems. Also, with limited or single use products, they are of smaller size than institutional products.
  • the exemplary embodiments for application can also be easily shipped, easily stored (e.g., suitcase, handbag, etc.), and much more affordable for the individual user.
  • the formulations described above can be administered by any means that other topical formulations can be administered.
  • they can be applied to the skin prior to application of a heat-generating appliance (mechanism), or can be applied directly to, embedded in (wholly or in-part), and so forth, into the heat-generating appliance (mechanism).
  • a heat-generating appliance mechanism
  • various combinations of modes for application and modifications thereto are considered within the scope of this disclosure.
  • the heat-inducing appliance (mechanism) may be, as non-limiting examples, in the form of self-heating booties, mitts, masks, body strips, bonnets, and so forth. Descriptions of these appliances are provided below.
  • a self-heating mitt or bootie can be devised by a multi-layered material (i.e. a "fabricated material") containing an exothermic material, bounded by permeable and/or non-permeable/semi-permeable layers.
  • a multi-layered material i.e. a "fabricated material”
  • an outer layer can be formed from an open-ended enclosure with a front and a back covering with a seal about its perimeter, or the outer layer may be of a single and unitary construction.
  • the open-ended enclosure can be shaped in the form of a mitt or glove capable of receiving a hand, or a foot or other extremity of the body.
  • a heating layer can be singly configured or symmetrically configured to form layers of heating panels.
  • the heating layer can be comprised of a first outer fabric layer, an exothermic layer, and a second outer fabric layer.
  • a nonwoven fabric or polymeric material can be utilized.
  • a liner can be placed interior to the heating layer and may be of a water- impermeable material to protect a hand or foot from direct exposure to the heating layer.
  • water-impermeable materials include natural and synthetic rubbers, polyvinyl chloride, ethylene- vinyl acetate copolymers, polyurethanes, acrylic ester polymers, polyamides and the like.
  • the liner can be provided with a topical having heat-enhancible or heat- activated skin properties as described above.
  • the liner may also include therapeutic compounds for pain relief such as camphor, menthol, capsaicin and witch hazel.
  • Herbal products such as natural extracts like green tea, grapefruit seeds and yucca root may also be suitable for use as a topical as well.
  • the liner may be "pre-configured” with the formulations or "post-configured” with the formulations.
  • a pre-configured mitt/bootie may require the removal of a seal or exposure of the formulation by some physical action, such as breaking a seal, shaking, and so forth.
  • the seal may be waterproof, if so desired. Also the removal of the seal may occur after the mitt/bootie is exposed to the activating solution.
  • mitt/bootie, etc. having the exothermic material, a convenient mechanism for generating heat is presented, as well as a mechanism for applying the above-described topicals/compositions.
  • a self-heating mask can be similarly devised using the multi-layered material described above.
  • a temperature controlled facial mask with area-specific treatments can include a substantially planar mask body which is formed with cut-outs for a person's eyes, nose, mouth, etc.
  • the face mask On the front side of the mask body, the face mask may include a number of treatment zones. The treatment zones can be coated with skin treatments/topicals, in the various manners, as described above.
  • a self-heating or cooling substrate may be applied to provide temperature control to the face mask.
  • small masks may be made having unique shapes to contour match a particular body part, such as a neck or shoulder for area- specific treatments.
  • a substrate can include a backing panel such as polyethylene or an absoiptive non-woven.
  • An upper panel such as an absorptive non-woven, can be positioned over the backing panel and a plurality of seals are made to form a number of pouches.
  • Each pouch contains an material, such as for heating (or cooling), or may be empty to provide neither heating (or cooling).
  • the pouches can also operate as treatment area to provide a number of very area- specific treatment zones. Accordingly, the mask may be made with any number of treatment zones, and any combination of heating, cooling or ambient (no heating or cooling) zones. In some instances, cooling is beneficial to treat Rosacea.
  • Straps may be formed about the mask to tie the mask onto the wearer's face to apply pressure to the mask and increase the contact area on the face.
  • the cosmeceutical formulations of the present invention can be distributed in the mask.
  • a pre-configured mask may require the removal of a seal or exposure of the formulation by some physical action, such as breaking a seal, shaking, and so forth.
  • the seal may be wateiproof, if so desired. Also the removal of the seal may occur after the mask is exposed to the activating solution.
  • a self-heating treatment bonnet can be similarly devised using versions of the multi-layered material described above.
  • a multi-layered disposable material can be utilized, (i.e., a "fabricated sheet"), housing an outer layer and an inner layer, with an intermediate layer of exothermic reactant.
  • Activation of the exothermic reactant is achieved by applying or soaking the exemplary embodiment(s) in an activating solution, such as an electrolyte solution or water, which triggers the exothermic reaction to generate the desired heat.
  • an activating solution such as an electrolyte solution or water
  • the multi-layered disposable material can be such that it can be manufactured from plastic, water proof paper, woven fabrics, foil, natural fibers, and so forth.
  • One layer of the multi-layered disposable material may be of a semi-permeable or even permeable material that permits entry of the activating solution into the exothermic reactant that is embedded or sandwiched therein.
  • an outer layer, inner layer, chamber and (optionally) activation solution entrance aperture can comprise the bonnet.
  • the user may reverse the "wearing" of the bonnet during mid-treatment to go from a dry heat treatment (impermeable layer being the inner layer) to a wet heat treatment (impermeable layer being the outer layer), or vice versus. Therefore, the user can be afforded either option, if so desired.
  • the bonnet may be "pre-configured” with the formulations or “post-configured” with the formulations at the "head-side” layer.
  • a pre-configured bonnet may require the removal of a seal or exposure of the formulation by some physical action, such as breaking a seal, shaking, and so forth.
  • the seal may be waterproof, if so desired. Also the removal of the seal may occur after the bonnet is exposed to the activating solution.
  • a self-heating treatment body strip can be similarly devised using versions of the multi-layered material described above.
  • the user may simply dip the sheet (with the permeable side exposed) into the activating solution (if using Lava GelTM, then water can be the activating solution) and letting the activating solution soak into the exothermic reactant that is bounded by the inner and outer layers. Some degree of shaking may be needed, to better distribute the activating solution.
  • the self-heating multi- layered fabricated sheet will rise to its desired/designed temperature and maintain itself at that temperature for an extended period of time. Using Lava GelTM, extended heat times of over an hour or more can be achieved.
  • both inner layer and outer layer may be desirable to have both inner layer and outer layer as impermeable layers, using a port or channel in either layer for introducing the exothermic activating solution.
  • no activating solution need be exposed to the elements (or drip out) after being applied to the self-heating multi-layered fabricated sheet, as well as the fact that with a permeable membrane or layer, heat can escape through the membrane, which could reduce its heating longevity.
  • the layers may be formed in strips (laterally alternating), whereby one strip or section of outer layer would be impermeable and another neighboring strip or section of outer layer would be permeable.
  • different regions of the self-heating multi-layered fabricated sheet would be heated.
  • An example would be the use of a wrap wherein only one section of the wrap would be self-heating, for localized heating (e.g., knee, calf, shoulder, etc.).
  • the permeable layer may have an impermeable tear-off covering, and by tearing off appropriate impermeable tear- off cover(s), selected portions or sections of the self-heating multi-layered fabricated sheet would be heated,
  • a sleeve may be formed from the exemplary multi-layered fabricated sheet.
  • the exemplary sleeve can be configured with shoulder-side opening, wrist-side opening, inner layer, outer layer and optional seams and optional protective area.
  • the inner layer and outer layer may be any combination of permeable/impermeable materials, as discussed above.
  • a leg or calf or other part of the body wrap may be contemplated.
  • Various portions or sections of the strip, sleeve, wrap, etc. may contain the topical/formulations described above, applied in any of the manners/combinations outlined.
  • the strip, sleeve, wrap, etc. may require the removal of a seal or exposure of the formulation by some physical action, such as breaking a seal, shaking, and so forth.
  • the seal may be waterproof, if so desired. Also the removal of the seal may occur after the appliance is exposed to the activating solution,

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des cosméceutiques topiques et leurs formulations. Dans un mode de réalisation, l’invention concerne l’administration transdermique de cosméceutiques renforcée par la chaleur au moyen de véhicules d’administration encapsulés dans des liposomes.
PCT/US2010/044919 2009-08-09 2010-08-09 Formulation cosméceutique topique et procédés de préparation et d’utilisation afférents WO2011019668A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23246509P 2009-08-09 2009-08-09
US61/232,465 2009-08-09

Publications (1)

Publication Number Publication Date
WO2011019668A1 true WO2011019668A1 (fr) 2011-02-17

Family

ID=43586419

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/044919 WO2011019668A1 (fr) 2009-08-09 2010-08-09 Formulation cosméceutique topique et procédés de préparation et d’utilisation afférents

Country Status (1)

Country Link
WO (1) WO2011019668A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147073A1 (fr) * 2013-03-21 2014-09-25 Koninklijke Philips N.V. Système pour distribuer des ingrédients cosmétiques sur la peau
WO2014009857A3 (fr) * 2012-07-10 2015-01-08 Koninklijke Philips N.V. Libération de molécules à partir d'un récipient par chauffage sélectif de cheveux
WO2015020499A1 (fr) * 2013-08-09 2015-02-12 Regeron, Inc. Composition pour améliorer des états cutanés comportant un fragment de la protéine de choc thermique 90a humaine en tant que principe actif
US20180311162A1 (en) * 2017-05-01 2018-11-01 Shen Wei (Usa) Inc. Skin barrier enhancing article and manufacturing method
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10822382B2 (en) 2013-08-09 2020-11-03 Regeron, Inc. Composition for improving skin conditions comprising a fragment of human heat shock protein 90A as an active ingredient
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2022183679A1 (fr) * 2021-03-03 2022-09-09 张铿 Couche d'administration de médicament transdermique
CN115252649A (zh) * 2022-09-28 2022-11-01 广州集妍化妆品科技有限公司 嗜热菌发酵产物在防脱发和/或生发中的用途、组合物及其制剂
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20070248633A1 (en) * 2006-04-21 2007-10-25 L'oreal Compositions containing a hydroxylated diphenylmethane compound, methods of use
US20080299092A1 (en) * 2007-04-27 2008-12-04 Mibelle Ag Cosmetic preparation and method for preparing the same
US20090007899A1 (en) * 2004-07-14 2009-01-08 Mycoal Products Corporation Wettable Heat Generating Composition Compressed Body, Heat Generating Body, and Process for Producing Wettable Heat Generating Composition Compressed Body

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310554A (en) * 1992-10-27 1994-05-10 Natural Carotene Corporation High purity beta-carotene
US20090007899A1 (en) * 2004-07-14 2009-01-08 Mycoal Products Corporation Wettable Heat Generating Composition Compressed Body, Heat Generating Body, and Process for Producing Wettable Heat Generating Composition Compressed Body
US20070237735A1 (en) * 2006-03-31 2007-10-11 Laboratoires Dermo-Cosmetik Inc. Anti-aging composition, kit and method of use
US20070248633A1 (en) * 2006-04-21 2007-10-25 L'oreal Compositions containing a hydroxylated diphenylmethane compound, methods of use
US20080299092A1 (en) * 2007-04-27 2008-12-04 Mibelle Ag Cosmetic preparation and method for preparing the same

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014009857A3 (fr) * 2012-07-10 2015-01-08 Koninklijke Philips N.V. Libération de molécules à partir d'un récipient par chauffage sélectif de cheveux
CN104428037A (zh) * 2012-07-10 2015-03-18 皇家飞利浦有限公司 通过选择性加热毛发从容器中的分子释放
WO2014147073A1 (fr) * 2013-03-21 2014-09-25 Koninklijke Philips N.V. Système pour distribuer des ingrédients cosmétiques sur la peau
WO2015020499A1 (fr) * 2013-08-09 2015-02-12 Regeron, Inc. Composition pour améliorer des états cutanés comportant un fragment de la protéine de choc thermique 90a humaine en tant que principe actif
US10822382B2 (en) 2013-08-09 2020-11-03 Regeron, Inc. Composition for improving skin conditions comprising a fragment of human heat shock protein 90A as an active ingredient
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11998575B2 (en) 2016-03-31 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
WO2018204403A1 (fr) * 2017-05-01 2018-11-08 Shen Wei (Usa) Inc. Article d'amélioration de barrière cutanée et procédé de fabrication
US20180311162A1 (en) * 2017-05-01 2018-11-01 Shen Wei (Usa) Inc. Skin barrier enhancing article and manufacturing method
WO2022183679A1 (fr) * 2021-03-03 2022-09-09 张铿 Couche d'administration de médicament transdermique
CN115252649A (zh) * 2022-09-28 2022-11-01 广州集妍化妆品科技有限公司 嗜热菌发酵产物在防脱发和/或生发中的用途、组合物及其制剂

Similar Documents

Publication Publication Date Title
WO2011019668A1 (fr) Formulation cosméceutique topique et procédés de préparation et d’utilisation afférents
US5885260A (en) Freeze-dried liposome delivery system for application of skin treatment agents
Asbill et al. Enhancement of transdermal drug delivery: chemical and physical approaches
JP4758915B2 (ja) 多重層リポソームおよびその製造方法
Barry Novel mechanisms and devices to enable successful transdermal drug delivery
US20180339166A1 (en) Delivery of large molecular weight biologically active substances
Akhtar Vesicles: a recently developed novel carrier for enhanced topical drug delivery
US20060222695A1 (en) Deoxycholic acid liposome-based dermatological topical preparation
Richard et al. Vesicular systems for dermal and transdermal drug delivery
CN105999535A (zh) 海绵骨针作为皮肤物理促渗剂的应用
Dayan Pathways for skin penetration
KR100976418B1 (ko) 수분 투과에 대하여 방향성을 지닌 시트를 이용한 마스크팩
KR100461458B1 (ko) 다중층 리포좀 및 그의 제조방법
US11510883B2 (en) Kit for delivery of an active compound into the skin
Atkinson et al. Targets in dermal and transdermal delivery and classification of penetration enhancement methods
CN116687780A (zh) 含多肽的靶向渗透组合物及其应用
JP6735426B2 (ja) カチオン化ベシクル及びその組成物
CN105496822A (zh) 果酸护肤液及其制备方法
KR20010083712A (ko) 리포좀 화장료 조성물 및 이를 제조하는 방법
KR102321532B1 (ko) 피부생리활성물질을 함유하는 리포좀 조성물 및 그의 제조방법
KR20020008598A (ko) 리포좀 화장료 조성물 및 이를 함유하는 부직포
CN113679631A (zh) 一种含有透明质酸的氨甲环酸脂质体化妆品及其制备方法
KR100428491B1 (ko) 항주름제를 함유하는 하이드로겔 시트 조성물
Blume Flexible liposomes for topical applications in cosmetics
CN110141657B (zh) 一种表皮生长因子脂质体及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10808600

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10808600

Country of ref document: EP

Kind code of ref document: A1